Lahore: Liven Pharma Limited has announced that its Board of Directors will convene on July 22, 2025, in Lahore to deliberate on a proposed increase in the company's authorized capital. The notification was intended for the TRE Certificate Holders of the Exchange, highlighting the significance of this meeting for stakeholders and investors.

The meeting's agenda focuses on strategic financial planning, with an emphasis on augmenting authorized capital, a move aimed at enhancing the company's fiscal capabilities and future growth prospects. The decision is pivotal as it could potentially influence the company's market position and investment appeal.

According to information available from the Pakistan Stock Exchange (PSX), the pharmaceutical sector remains a key component of the designated market category, reflecting ongoing interest and activity within this industry. The outcome of the meeting is anticipated to have implications for Liven Pharma Limited's business operations and market performance.

Stakeholders are advised to stay informed about the developments from the forthcoming meeting, which could lead to significant changes in the company's capital structure, aligning with its long-term strategic objectives.